ERIS Lifesciences Ltd's Q4FY18 consolidated net profit rises 20.57% yoy to Rs56.10cr : In-line with Estimates

The company’s consolidated revenue stood at Rs212.19cr, up 15.52% yoy and 1.54% qoq.

May 25, 2018 10:05 IST India Infoline Research Team

ERIS Lifesciences Ltd Q4FY18

Consolidated Results Q4FY18: (Rs. in cr)

Q4FY18 YoY (%)
Revenue 212.19 15.5
EBITDA 71.73 46.2
EBITDA Margin (%) 33.8 710
Net Profit (adjusted) 56.10 20.6
***EBITDA margin change is bps


Reco. Price


Last updated on


Eris Lifesciences’ sales in Q4FY18 grew by 15.5% yoy to Rs212.2cr. EBITDA grew by 46.2%yoy to Rs71.73cr in Q4FY18, EBITDA margins were at 33.8% in Q4FY18 vs. 38.8% in Q3FY18 and 26.7% in Q4FY17. PAT grew by 20.6% yoy to Rs56.1cr in Q4FY18.
  • The numbers are not comparable, as company has bought the domestic branded business of Strides Shasun in FY18.
  • Eris’ sales and EBITDA is above the street estimates, while PAT is slightly below estimate.
  • Gross margin at 84.5% in Q4FY18 vs. 83.9% in Q3FY18 and 84.6% in Q4FY7. The numbers show that the company is on track to successfully merge the domestic business of Strides Shasun

Technical View:

ERIS Lifesciences Ltd is currently trading at Rs. 775.90, up by 11.5 points or 1.5% from its previous closing of Rs. 764.40 on the BSE.
The scrip opened at Rs. 772.70 and has touched a high and low of Rs. 784 and Rs. 764.40 respectively. So far 13,942 (NSE+BSE) shares were traded on the counter. The stock is currently trading above its 50 DMA.

Related Story